Risk factors for liver-related mortality in chronic hepatitis C patients: A deceased case-living control study

Table 4 Adjusted multivariate conditional logistic regression analysis of potential risk factors for chronic hepatitis C mortality n (%)

Variable	Cases (n = 144)	Controls (n = 576)	AOR (95%CI)	B	P value
Initial diagnostic stage
CHC	55 (38.19)	404 (70.14)	1.00 (Reference)	NA	NA
LC	60 (41.67)	152 (26.39)	2.89 (1.83-4.56)	1.06	0.000
HCC	29 (20.14)	20 (3.47)	8.82 (3.99-19.53)	2.18	0.000
HBsAg negativity	125 (86.81)	570 (98.96)	1.00 (Reference)	NA	NA
HBsAg positivity	19 (13.19)	6 (1.04)	22.28 (5.58-89.07)	3.10	0.000
Without diabetes	102 (70.83)	464 (80.56)	1.00 (Reference)	NA	NA
With diabetes	42 (29.17)	112 (19.44)	2.35 (1.40-3.95)	0.86	0.001
Without antiviral therapy	126 (88.89)	392 (73.78)	1.00 (Reference)	NA	NA
With antiviral therapy	16 (11.11)	151 (26.22)	0.53 (0.28-0.99)	-0.64	0.048
Without hypertension	99 (68.75)	452 (78.47)	1.00 (Reference)	NA	NA
With hypertension	45 (31.25)	124 (21.53)	1.76 (1.09-2.82)	0.56	0.020
Without alcohol consumption	92 (63.89)	419 (72.74)	1.00 (Reference)	NA	NA
With alcohol consumption	52 (36.11)	157 (27.26)	1.70 (1.03-2.81)	0.53	0.037
Anti-HBc negativity	48 (33.33)	263 (45.66)	1.00 (Reference)	NA	NA
Anti-HBc positivity	96 (66.67)	313 (54.34)	NA	NA	0.946

AOR: Adjusted odds ratios; B: Regression coefficient; CHC: Chronic hepatitis C; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; NA: Not applicable; HBsAg: Hepatitis B surface antibody; Anti-HBc: Anti-hepatitis core antibody.